摘要
目的对比分析替吉奥和紫杉醇作为同步放化疗方案治疗非手术食管癌的疗效比较.方法回顾性分析88例食管鳞癌患者临床资料,替吉奥组和紫杉醇组各44例.放疗方案为1.8~2 Gy/次,共照射45~60 Gy.替吉奥方案:剂量根据体表面积决定,21 d 1个周期.紫杉醇方案:紫杉醇40 mg/m^(2),周方案.统计分析两组的生存及毒副反应.结果替吉奥组和紫杉醇组的1、2、3年生存率分别为77.3%、65.9%、31.6%和75.0%、47.6%、37.8%(P=0.610),1、2、3年无进展生存率分别为54.5%、40.9%、22.2%和52.3%、29.0%、20.2%(P=0.905).客观缓解率与疾病控制率差异无统计学意义(P>0.05).替吉奥组的酸痛和四肢麻木发生率显著低于紫杉醇组(P<0.01).结论替吉奥联合放疗和紫杉醇联合放疗的近期疗效和生存率相近,但是替吉奥毒副作用更轻且口服方便,值得临床进一步推广和研究.
Objeetive To analyze the eficacy and safety of single-agent S-1 and single-agent palitaxel as concurrent chemoradiotherapy regimen for non-surgical esophageal carcinoma. Methods The clinical data of 88 patients with esophageal squamous cell carcinoma were rerspectively analyzed. The patients were divided into S-1 group and paclitaxel group, with 44 people each. Fractionated radiation therapy was adopted, 1.8~2 Gy/fraction, totally imadiating 45~60 Gy. For the S-1 group, patients ’drug doses were depended on their body surface area. 21 days were a period. For the paclitaxel group, patients took a dose of 40 mg/ m^(2) weekly. Statistical analysis was conducted on the survival prognosis and toxic ffects of the two groups.Results The 1-,2-. and 3-year survival rates of the S-1 group were 77.3%,65.9%, and 31.6%,respectively, while that of the pacitaxel group was 75.0%,47.6% and 37.8% ( P=0.610) . The progressive- free survival rate of the S-1 group for 1, 2 and 3 years was 54.5%,40.9% and 22.2%,while that of the paclitaxel group was 52.3%,29.0% and 20.2% ( P=0.905 ) . There was no signifiant difrerence in the objecive remission rate and disease control rate between the two groups. The incidence of soreness and numbness in the S-1 group was significantly lower than those in the pacitaxel group ( P<0.01 ) .Conclusion The short-term eficacy and survival rates of paclitaxel and S-1 combined with radiotherapy are similar, but S-1 has slighter toxic and side effect and it' s convenient to take orally.
出处
《浙江临床医学》
2021年第4期463-465,共3页
Zhejiang Clinical Medical Journal
基金
国家自然科学基金资助项目(81874217、81703027、81703028、81672983)。
关键词
替吉奥
紫杉醇
食管癌
预后
S-1
Paclitaxel
Esophageal cancer
Prognosis
